Case Report
A fatal case of pneumonitis and hypogammaglobulinemia with use of a CDK4/6 inhibitor in metastatic breast cancer: case report
Translational Breast Cancer Research
2022;
3:
9
(31 January 2022)
Original Article
Sequential versus concurrent adjuvant chemo-endocrine therapy for HR+ early breast cancer: a systematic review and Bayesian network meta-analysis
Translational Breast Cancer Research
2022;
3:
8
(31 January 2022)
Editorial Commentary
Monarch plus: a research review
Translational Breast Cancer Research
2022;
3:
7
(31 January 2022)
Editorial Commentary
Endocrine therapy leads the first- and second-line treatment options for hormone receptor-positive advanced breast cancer—comments on the Monarch plus study
Translational Breast Cancer Research
2022;
3:
6
(31 January 2022)
Editorial Commentary
MONARCH-plus: the evidence of efficacy and safety of abemaciclib in countries with limited clinical research opportunities
Translational Breast Cancer Research
2022;
3:
5
(31 January 2022)
Review Article
A narrative review of the clinical development of CDK4/6 inhibitor abemaciclib in breast cancer
Translational Breast Cancer Research
2022;
3:
4
(31 January 2022)
Review Article
Role of abemaciclib in primary breast cancer: a narrative review of MonarchE
Translational Breast Cancer Research
2022;
3:
3
(31 January 2022)
Review Article
Innovation drug approvals based on a bridging study: from concept to practice
Translational Breast Cancer Research
2022;
3:
2
(31 January 2022)
Meet the Professor
The legend of MONARCH: Chinese breast cancer experts from participation in to leading global clinical study and boosting treatment area development
Translational Breast Cancer Research
2022;
3:
1
(31 January 2022)
